The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms.
Toby Johnson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Chun-fang Xu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer/Onyx; Genentech; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer
Keith C. Deen
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Zhengyu Xue
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Arundathy N. Bartlett-Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Christopher Carpenter
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert John Motzer
Consultant or Advisory Role - Genentech; Pfizer
Research Funding - Astellas Pharma; AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer